Clinical Trials Logo

Clinical Trial Summary

participants will be receiving OMT 1x/week for 8 weeks. Each appointment with be a duration of 30 minutes. Patients will be required to fill out PHQ-9 and SSS-8 questionnaires before beginning the study and following the conclusion of the study.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05065580
Study type Interventional
Source Spectrum Health - Lakeland
Contact
Status Recruiting
Phase N/A
Start date March 12, 2021
Completion date October 2022

See also
  Status Clinical Trial Phase
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Recruiting NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Suspended NCT02940769 - Neurobiological Effects of Light on MDD Early Phase 1
Recruiting NCT04556890 - Pain and Major Depressive Disorder N/A
Recruiting NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Active, not recruiting NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Active, not recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT04799405 - Home-based tDCS in Major Depressive Disorder N/A
Recruiting NCT04422652 - Combination of Novel Therapies for CKD Comorbid Depression Phase 2
Recruiting NCT03708159 - Maintenance of Response After rTMS for Depression Using tDCS N/A
Recruiting NCT03363919 - Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression N/A
Recruiting NCT04727229 - Stellate Ganglion Block for Major Depressive Disorder. Phase 4
Enrolling by invitation NCT04634669 - Open-Label Safety Study of AXS-05 in Subjects With TRD Phase 2
Recruiting NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Completed NCT03113890 - McLean and Genomind Prospective Study N/A
Recruiting NCT04130958 - Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics N/A
Recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Enrolling by invitation NCT05061719 - An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3